RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m^(6)A modification  

作　　者：Yahui Zhao Yang Li Rui Zhu Riyue Feng Heyang Cui Xiao Yu Furong Huang Ruixiang Zhang Xiankai Chen Lei Li Yinghui Chen Yuhao Liu Jinhua Wang Guanhua Du Zhihua Liu 

机构地区：[1]State Key Laboratory of Molecular Oncology,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]Department of Oncology,Cancer Institute,Peking University Shenzhen Hospital,Shenzhen Peking University-Hong Kong University of Science and Technology(PKU-HKUST)Medical Center,Shenzhen 518035,China [3]Department of Thoracic Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China [4]Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen 518116,China [5]School of Life Sciences,Tsinghua University,Beijing 100084,China [6]Key Laboratory of Drug Target Research and Drug Screen,Institute of Materia Medica,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100050,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第7期3400-3414,共15页信号转导与靶向治疗（英文）

基　　金：The authors are grateful to Dr.Zhi Lu(Tsinghua University,China)for kindly providing RNA-seq analysis and ribosome-seq analysis technique direction.The authors are grateful to Dr.Yutaka Shimada(Kyoto University,Japan)for the ESCC cell lines.The authors appreciate Cong Liu(Sinsage Technology Co.LTD)for providing the Livecyte single-cell tracking imaging analysis system.The authors thank Novogene Bioinformatics Technology Co.,Ltd.,Beijing,for assistance during the Ribosome-seq analysis.This work was supported by the National Natural Science Foundation of China(82188102,81903025,82273453 and 82030089);National Key R&D Program of China(2021YFC2501000 and 2020YFA0803300);CAMS Innovation Fund for Medical Sciences(2021-1-I2M-1-018,2022-I2M-2-001 and 2021-I2M-1-067);the Fundamental Research Funds for the Central Universities(3332021091).

摘　　要：Increased rates of ribosome biogenesis have been recognized as hallmarks of many cancers and are associated with poor prognosis.Using a CRISPR synergistic activation mediator(SAM)system library targeting 89 ribosomal proteins(RPs)to screen for the most oncogenic functional RPs in human esophageal squamous cell carcinoma(ESCC),we found that high expression of RPS15 correlates with malignant phenotype and poor prognosis of ESCC.

关 键 词：ESOPHAGEAL SQUAMOUS PROGNOSIS 

分 类 号：R735.1[医药卫生—肿瘤]